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Summary 
Cytosine deaminase (CD)/5-fluorocytosine (5-FC) and herpes simplex 
virus thymidine kinase (HSVtk)/ganciclovir (GCV) systems are the most 
well-studied and extensively used suicide gene/prodrug systems in 
cancer gene therapy. In this study, we evaluated and compared the 
inhibitory effects of HSVtk/GCV and CD/5-FC on glioma development. 
In vitro results indicate that when delivered by suicide gene expression 
in the U87 glioma cell line and in neural stem cells (NSCs), the CD/5-FC 
system was able to induce a bystander killing effect stronger than that 
of the HSVtk/GCV system, thus being more effective in eliminating 
glioma cells. Intratumoral injection of NSCs expressing the CD gene 
into BALB/c nude mice harboring U87 glioma xenografts induced 
significant tumor regression, and tumor growth was inhibited when 5-FC 
was administered. Bacterial CD/5-FC and yeast CD/5-FC displayed 
similar anti-glioma effects in vitro and in vivo. These results suggested 
that the antiglioma effect of the CD/5-FC system is superior to the 
HSVtk/GCV system, with the former being more suitable for glioma 
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1.1 Characteristics and Conventional Therapies for Glioblastoma 
Glioblastoma which derives from glial cells is a tumor of primary central 
nervous system. According to the World Health Organization (WHO), 
gliomas can be categorized by either their aggressiveness or by cell 
type. Aggressiveness ranges from grade I, the pilocytic astrocytoma of 
young adults and children, to grade IV, the most malignant form with the 
worst prognosis (Louis et al., 2007). High-grade gliomas are generally 
associated with poor prognosis (Kleihues et al., 2007). Indeed, the 
median survival of the glioblastoma multiforme (GBM) bearing patients 
is only ~1 year, and less than 5% of patients are able to survive 3 years 
or more (Hassan et al., 2007). The primary types of glioma cells are 
ependymomas and astrocytomas of which GBM is the most common. 
 
Hereditary genetic mutations and environmental factors may increase 
the risk of developing a glioma. For instance, diets high in N-nitroso 
compounds may elevate the risk of getting glioma for adults (Ohgaki 
and Kleihues, 2005). However, the main cause of gliomas still remains 
unknown. 
 
Gliomas are highly infiltrative and can migrate along paths which 
include perivascular, perineuronal and subpial spaces. Moreover, 
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gliomas can migrate into white matter (Holland, 2000). Overexpression 
of matrix metalloproteinases (MMPs) in gliomas influences glioma 
migration. Furthermore, invasion of tumor cells is regulated by several 
proteins, such as proline-rich tyrosine kinase (PYK2), Rho proteins and 
focal adhesion kinase (FAK) (Anders et al., 2007). 
 
Surgical resection together with radiotherapy and/or chemotherapy is 
current conventional glioma therapy. This therapeutic approach may 
prolong the survival of patients (ranging from 3 to 9 months) as well as 
improve life quality. Surgical resection alone can remove up to 99% of 
GBM (from 1011 cells to 109). A greater extent of tumor removal is 
associated with longer survival time. However, it is impossible to 
remove the entire tumor mass because of the invasive and infiltrative 
nature of gliomas. Furthermore, tumor edge cannot be clearly defined 
which would compromises the effect of surgery and results in tumor 
recurrence (Sneed et al., 1994). Surgical resection combined with 
radiotherapy results in better prognosis than surgical resection only. 
The median survival for the surgery only group is significantly less than 
that for the surgery and radiotherapy group (Whittle et al., 1991). 
However, normal brain tissues are only able to tolerate up to 60 Gy of 
radiation, which is below the requirement for glioma cell death. Adjuvant 
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chemotherapy plays a role in improving the survival of BGM. 
Radiotherapy combined with chemotherapy yields an increase in 
survival at 1 and 2 years by 10.1 and 8.6%, respectively (Fine et al., 
1993). However, the existence of the blood-brain barrier may hinder the 
transport of many chemical drugs and causes the failure of 
chemotherapy. Hence, the current conventional curative treatment for 
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1.2 Gene Therapy for Gliomas 
Because the outcome of conventional approaches is unsatisfactory, 
novel therapeutic strategies are urgently needed. As a promising new 
cancer therapy approach, gene therapy is a technique which involves 
introduction or removal of genes within cells to treat diseases. Since the 
first clinical trial involving human gene therapy in 1989 (Rosenberg et al., 
1990), more than 1340 trials have been completed, and most of them 
(65%) aim to treat cancer (Edelstein et al., 2007). The location of a 
glioma in the CNS (where it is anatomically restricted and lacks 
metastases outside the CNS) makes it an attractive target for gene 
therapy by allowing the vector to deliver therapeutic genes directly to 
tumor. Furthermore, it could avoid damage to normal tissue and 
reduces side effects (Immonen et al., 2004). 
 
1.2.1 Viral Vectors 
Several viral vectors have been employed in cancer gene therapy, with 
retroviral and adenoviral vectors being the most common for glioma 
therapy. During retrovirus transduction, double-stranded DNA which is 
transcribed from viral RNA is able to integrate into the chromosome of 
transduced cells. Hence, target cells display high and stable expression 
of the transduced gene. However, random gene integration is a 
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controversial safety issue. In addition, low transduction efficiency in vivo 
limits the further application of retroviral vectors (Rainov and Ren, 2003; 
Vile and Russell, 1995). 
 
In contrast to retroviruses, adenoviruses have high transduction 
efficiency. However, because there is no integration into the host 
genome, the use of adenoviral vectors does not cause unwanted 
mutagenesis. The safety of adenoviral vectors has been proven in 
several clinical trials (Trask et al., 2000, Immonen et al., 2004). Another 
advantage of adenoviral vectors is that they can elicit immune 
responses, which may provide additional antitumor effects (Danthinne 
and Imperiale, 2000; Kay et al., 2001; Sandmair et al., 2000).  
However, several weaknesses of adenoviral vectors limit their 
application. The expression of the transduced gene is transient because 
no DNA integration is involved. In addition, the adenovirus is a common 
human pathogen. Hence, pre-existing immune responses may hamper 
the in vivo delivery of adenoviruses. 
 
Baculoviruses (Autographa californica multiple nucleopolyhedrovirus) 
are emerging as vectors for gene therapy. Compared with conventional 
viral vectors, the baculovirus has several attractive features that make it 
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a promising viral vector for gene therapy. As an insect virus, baculovirus 
does not replicate within mammalian cells. Viral gene integration is rare, 
and no viral genes are expressed during viral transduction. (Ghosh et 
al., 2002). The side effects are minimal, and no safety issues have been 
reported thus far. Because humans are not the natural host for 
baculovirus, no pre-existing specific immune response against the 
baculovirus exists, which provides an additional advantage. Scientists 
have successfully transduced the baculoviruses which undergo genetic 
modification to contain mammalian expression cassettes into a broad 
range of mammalian cells, including embryonic stem cells (Zeng et al., 
2007), mesenchymal stem cells (Ho et al., 2005), keratinocytes 
(Condreay et al., 1999) and chondrocytes (Ho et al., 2004). Besides, 
Baculoviruses can be employed to transduce cancer cells with high 
efficiency. Wang et al. (2006) showed that the baculovirus transduction 
efficiency of glioma cells can reach 98%. Other advantages of 
baculoviruses include a large (100-kb) cloning capacity, ease of vector 
construction, a simple virus preparation procedure and the virtual 
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1.2.2 Neural Stem Cells (NSCs) and the Use of NSCs for Glioma 
Therapy  
NSCs are a self-renewing and multi-potent population that gives rise to 
three major neural lineages: neurons, astrocytes and oligodendrocytes. 
NSCs reside in neurogenic regions in the brain, such as the 
subventricular zone (SVZ), from which NSCs can be obtained (James, 
2004). Embryonic stem cells are also able to generate NSCs 
(Alvarez-Buylla and Doetsch, 2002). Attracted by various signals such 
as growth factors and chemokines, NSCs display migratory behavior 
toward intracranial pathologies, including neoplastic lesions. 
Furthermore, transplanted NSCs demonstrate a tropism both toward a 
glioma mass as well as infiltrative “satellite” glioma cells in animal 
models (Aboody et al., 2000; Benedetti et al., 2000; Glass et al., 2005). 
The gliomatropism of NSCs suggest that they are an ideal vector for 
delivering therapeutics to gliomas. NSCs expressing suicide genes 
produce powerful cytotoxicity toward glioma cells via a bystander effect  
(Aboody et al., 2000; Barresi et al., 2003; Boucher et al., 2006; Danks et 
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1.3 Suicide Gene/Prodrug System Used in Gene Therapy 
Gene therapy is one of the most promising new frontiers in medical 
therapeutic intervention, especially in tumor therapy. Currently used 
applications in glioma gene therapy are primarily tumor suppressor and 
cell cycle modulation, genetic immune modulation, transfer of 
anti-angiogenic factors and prodrug-activating gene therapy (Kaveh and 
Antonio, 2009). 
 
The suicide gene/prodrug system is an approach which is commonly 
used in glioma gene therapy. Cells which were transduced with specific 
suicide genes can produce enzymes which catalyze the conversion of 
prodrug, from its non-toxic form to toxic form, allowing it to induce a 
therapeutic effect on tumor cells. High level of intratumoral 
chemotherapy can be achieved by conversion of prodrug, which is a 
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1.3.1 Herpes Simplex Virus Type 1 (HSV-1) Thymidine 
Kinase(HSVtk)/Ganciclovir(GCV) 
Moolten (1986) first reported the HSVtk/GCV system. Nontoxic GCV is 
converted into monophosphorylated GCV-p by the HSVtk protein. The 
travel of GCV-p to neighboring cells depends on gap junctions (Drake et 
al., 2000; Sanson et al., 2002). GCV-p is able to be further 
phosphorylated to cytotoxic GCV triphosphate. Incorporation of GCV 
triphosphate into newly synthesized DNA causes chain termination and 
breaks the double-stranded DNA, ultimately resulting in cell death via 
apoptosis (Beltinger et al., 1999; Boucher et al., 2006; Molten et al., 
1986; Moolten 1990). The bystander effect of HSVtk/GCV is exerted by 
transportation of phosphorylated GCV to HSVtk-negative cells through 
gap junctions. Over-expression of connexin43, which is a key gap 
junction-related protein, can enhance the bystander effect (Yang et al., 
1998; Vrionis et al., 1997). 
 
As the most well-studied suicide gene therapy system, HSVtk/GCV has 
received increasing attention recently. Intra-tumoral injection of NSC 
expressing HSVtk followed by GCV administration is reported to 
completely eliminate gliomas, and experimental rats can be maintained 
tumor-free for 10 weeks under this regime (Li et al., 2005). A previous 
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study in our lab also suggests that HSVtk/GCV is efficient in preventing 
tumor growth in glioma animal model (Bak et al., 2010). This therapeutic 
effect against gliomas can be further improved by enhancing the gap 
junctions between tumor cells. Histone deacetylase inhibitor 
4-phenylbutyrate (4-PB) is able to enhance gap junction communication 
in vitro. Thus, by the co-administration of the 4-PB and HSVtk/GCV, the 
bystander effect against glioma can be dramatically enhanced 
compared to single use of HSVtk/GCV (Ammerpohl et al., 2004). Gap 
junction may be restored by the over-expression of connexin43 which 
leads to the enhancement of bystander effect induced by HSVtk/GCV 
system. Expression of HSVtk combined with the over-expression of 
Cx43 has shown promising anti-glioma effects and holds potential for 
future glioma gene therapy as a novel approach (Huang et al., 2010). 
The bystander effect induced by HSVtk/GCV may also be further 
improved by creating a fusion protein containing HSVtk and a TAT 
peptide as a cargo carrier for different proteins (Dietz and Bahru, 2004). 
Thus, the fusion of HSVtk and TAT enhances the bystander effect of 
HSVtk/GCV by encouraging suicidal protein to move to non-transduced 
neighboring cells (Merilainen et al., 2005). 
 
HSVtk gene therapy has gone through clinical trial and the phase I 
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clinical trial protocols have been conducted. The first clinical trial was 
performed by Klatzmann in 1998, and other groups have followed suit 
(Kun et al., 1995; Oldfield et al., 1993; Raffel et al., 1994). Retroviral 
vector-producing cell (VPC)-mediated HSVtk was proven to be safe by 
the injection of HSVtk-positive VPCs into gliomas. Subsequently, 
HSVtk/GCV treatment increases the survival times of patients who 
suffer from malignant gliomas. In one study, the mean survival of 
patients who received HSVtk/GCV treatment increased to 71 weeks, 
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1.3.2 Cytosine Deaminase(CD) / 5-Fluorocytosine(5-FC) 
Both the codBA operon from Escherichia coli and the FCY1 gene from 
yeast (Saccharomyces cerevisiae) are able to encode cytosine 
deaminase (Danielsen et al., 1992; Erbs et al., 1997). CD deaminates 
nontoxic 5-fluorocytosine (5-FC) into the potent chemotherapeutic drug 
5-fluorouracil (5-FU). 5-FU can be converted into 
5-fluoro-20-deoxyuridine-50-monophosphate (5-FdUMP), which blocks 
thymidylate synthase, or into 5-fluorouridine-50-triphosphate (5-FUTP), 
which disrupts RNA functions by incorporation. 5-FdUTP can be 
metabolized from the precursor’s 5-FUTP and 5-FUDP, and 
incorporated into DNA, leading to cell death in the S-phase of the cell 
cycle (Thomas and Zalcberg, 1998). 
 
CD/5-FC treatment has pronounced antitumor effects toward gliomas. 
Chen et al. (2007) reported that the combination of hypoxia-inducible 
CD/5-FC treatment and radiotherapy exerts stronger bystander effect 
and radiosensitizing effect, without causing damage to normal cells 
(Chen et al., 2007). Furthermore, yeast CD/5-FC therapy can 
remarkably prolong the survival time of mice harboring orthotopic 
human glioma xenografts (Tai et al., 2005). 
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Yeast Cytosine Deaminase (yCD) and bacterial Cytosine Deaminase 
(bCD) are two separate forms of naturally evolved CD. Both forms have 
been extensively used and studied in gene therapy. However, the use 
of bCD is limited by its poor efficiency in deaminating 5-FC (West et al., 
1982). Compared to bCD, Kievit and colleagues have reported that yCD 
has a 22-fold lower Km for the prodrug 5-FC and the amount of 5-FU 
produced by yCD in vivo is 15-fold higher. In addition, yCD/5-FC has 
shown improved radiosensitivity and a stronger bystander effect in nude 
mice bearing human colorectal cancer xenografts compared to 
bCD/5-FC (Kievit et al., 1999; Kievit et al., 2000). Although yCD/5-FC 
has promising antitumor effects, the fact that yCD is less thermostable 
than bCD limits its application. Furthermore, the product released from 
yCD is rate limiting (Katsuragi et al., 1987; Yao et al., 2005). 
 
Unlike cytotoxic GCV-TP, 5-FC can diffuse out of the cell and produce a 
powerful bystander effect. CD-expressing tumor cells under 5FC 
treatment can result in great tumor regression even when the 
percentage of CD positive tumor cells is as low as 5% (Kuriyama et al., 
1998). 5-FC can diffuse freely through the cell membrane by 
non-facilitated diffusion (Huber et al., 1994; Miller et al., 2002) and 
doesn’t depend on gap junctions that require close proximity between 
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cells. In addition, 5-FU is a radiosensitizing chemotherapeutic 
anti-carcinomas agent (Austin and Huber, 1993). Thus, CD/5-FC 
treatment is able to induce radiosensitization in tumor cells (Khil et al., 
1996; Rogulski et al., 2008; Stackhouse et al., 2007). Because gene 
therapy cannot be the sole treatment in patients, the radiosensitizing 
effects of CD can augment treatment regimens, yielding an additional 
advantage of CD/5-FC treatment. As CD/5-FC and HSVtk/GCV are 
widely used in cancer gene therapy, several studied have compared the 
efficiency of these two systems in eliminating tumors in vitro as well as 
in vivo. Compared to HSVtk/GCV system, the use of CD/5-FC in cancer 
gene therapy causes a greater bystander effect. The major reason for 
this greater effect is that the diffusion of 5-FU does not require gap 
junctions, which are required for the transportation of GCV-p (Holder et 
al., 1993; Hotz et al., 1993). Because gap junctions are often absent in 
tumor cells, CD/5-FC may induce a stronger bystander effect and thus 
be superior to the HSVtk/GCV system. In the R3327 AT‐1 rat prostate 
tumor cell line transfected with a bifunctional fusion gene CDglyTK 
which is able to express a CD-TK fusion protein fused by the linkage of 
glycine spacer, CD/5-FC displays a more pronounced anti-tumor effect 
in vitro, but this system is less effective in eliminating the tumor in vivo 
(Corban et al., 2003). In other experiments, CD/5-FC therapy produces 
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a stronger bystander effect than HSVtk/GCV both in vitro (Kuriyama et 
al., 1999) and in vivo (Quynh et al., 1995). Synergistic anticancer effects 
of HSVtk/GCV and CD/5-FC therapies have also been studied. The 
combination of both gene-directed enzyme/prodrug therapy systems 
demonstrates an enhanced inhibitory effect on different cancer cell lines 
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1.4 Objectives 
5-FU is widely believed to freely diffuse through the cellular membrane, 
delivering cytotoxic metabolic product to cells distant from the 
CD-expressing cells. Hence, CD/5-FC is considered superior to the 
HSVtk/GCV system for cancer gene therapy. Although several reports 
have compared the antitumor effects of these suicide gene/prodrug 
systems in different cancer cell lines, the inhibitory effects of the 
CD/5-FC and HSVtk/GCV systems directed by neural stem cells on 
glioma development have not been systematically studied. In addition, 
the anti-glioma effect of yCD/5-FC and bCD/5-FC have not been 
evaluated and compared. Thus, this study aimed to directly compare 
the efficiency of the bystander killing effects of yCD/5-FC, bCD/5-FC 
and HSVtk/GCV on gliomas. We analyzed the cytotoxic effect of these 
three systems on glioma cells in vitro and in a xenograft glioma mouse 
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2.1 Cell culture and Tissue samples 
Human glioblastoma U87MG cell line was purchased from ATTC 
(Manassas, VA, USA) and cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 1% 
penicillin-streptomycin and 1% L-glutamine at 37°C, 5% CO2. U87MG 
cell was subcultured at ratio of 1:4 to 1:6 twice or three times a week. 
 
The stable U87 cell clone expressing luciferase gene (U87-luc) was 
derived from U87MG cell. U87-luc cell was maintained in U87 medium 
supplemented with additional 500 mg/ml geneticin at 37°C, 5% CO2.  
 
Neural stem cells which were derived from human embryonic stem cells 
b were maintained in DMEM/f12(1:1) (Invitrogen, CA, USA) containing 1% 
penicillin and streptomycin, 1% L-glutamine, 20ng/ml basic Fibroblast 
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2.2 Plasmid Construction 
2.2.1 PCR Amplification of CodA and Fcy Genes 
Vector pORF-CodA and pORF-Fcy were purchased from Invivogen, 
USA. Vector NTI program was used to design relevant primers for the 
PCR amplification. The PCR SuperMix High Fidelity kit (Invitrogen, CA, 
USA) was used to carry out the PCR and the PCR product was 
analyzed on a 1.2% agarose gel containing 0.1μl/ml of SYBR Green. 
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Figure 2.1 Schematic representation of the pORF-CodA plasmid 
constructs.  
 
Step Conditions cycles 
1 94°C, 3 min 1 
2 94°C, 45 sec 
30 3 55°C, 45 sec 
4 72°C, 90 sec 
5 4°C hold 




Forward Primer: 5’- GCGGAATTCATGAGCAATAACGCTTTAC -3’ 
Reverse Primer: 5’- ACGCTCGAGTCAACGTTTGTAATCGA -3’ 
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Figure 2.2 Schematic representation of the pORF-Fcy plasmid 
constructs. 
 
Step Conditions cycles 
1 94°C, 3 min 1 
2 94°C, 45 sec 
30 3 55°C, 45 sec 
4 72°C, 45 sec 
5 4°C hold 
Table 2.2 PCR conditions for amplification of Fcy from vector pORF-Fcy 
 
Fcy Primers 
Forward Primer: 5’- AGGAATTCATGGTGACAGGGGGAATG -3’ 
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2.2.2 Cloning into pFastBacTM1 Vector 
pFastBacTM1 containing CMV promoter, Woodchuck Hepatitis Virus 
(WHP) Posttranscriptional Regulatory Element (WPRE) and HSVtk 
gene with flanking EcoRI and XhoI sites was generated by Bak Xiaoying. 
The vector was double-digested by EcoRI and XhoI restriction enzyme 





























Figure 2.3 Schematic representation of the pFastBacTM1constructs. The 
figure shows the constructs used to produce recombinant baculoviruses. 
a) pFastBacTM1 vector map b) (i) CMV-HSVtk-WPRE (ii) 
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2.3 Baculovirus Production 
Baculoviruses were produced and propagated in Spodoptera frugiperda 
(Sf9) insect cells grown in Sf-900 II serum-free medium according to the 
manual of the Bac-to-Bac Baculovirus Expression System (Invitrogen, 
CA). 
 
For bacmid production, 9 X 105 Sf9 cells per well were seeded in a 
6-well plate and allowed to attach for an hour. The diluted bacmid DNA 
was combined with the diluted Cellfectin@Reagent (Invitrogen, CA) and 
incubated for 15 to 45 minutes at room temperature. The medium was 
then replaced by the combination of bacmid DNA and Cellfectin reagent 
in unsupplemented Grace’s Medium (Invitrogen, CA, USA). Cells were 
incubated in 27°C incubator for 5 hours and then the unsupplemented 
Grace’s Medium was replaced with Sf-900 II serum-free medium. P1 
virus can be harvested after 72 hours incubation in 27°C incubator. 
 
P3 virus was propagated from P1 virus according to the manual. 
Budded viruses in the Sf-900 II serum-free medium were centrifuged at 
500 g for 5 min to remove cell debris. The supernatant was stored at 
4°C and kept from light. The viral titres were determined by qPCR. 
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2.4 Confirmation of Gene Expression 
2.4.1 RNA Extraction 
Cells were transduced by baculovirus 1 day before the RNA extraction. 
TRIZOL® Reagent (innitrogen, CA) was used to extract total RNA from 
transduced U87 cells or NSC stem cells according to manufacturer’s 
manual. Briefly, 1ml TRIZOL reagent was used to homogenize cells 
growing on 6-well plate, followed by centrifugation at 12000g for 10 min 
at 2-8°C. 0.2 ml of chloroform per 1 ml of TRIZOL Reagent was added 
and mixed with homogenized samples by vigorous shaking. Sample 
was incubated at room temperature for 3 minutes and then centrifuged 
at 12,000 g for 15 minutes at 4°C. The aqueous phase was transferred 
to another fresh tube and mixed with isopropyl alcohol to precipitate the 
RNA. After 75% ethanol washing, the briefly dried RNA pellet was 
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2.4.2 Reverse transcriptase PCR (RT-PCR)  
Turbo DNA-freeTM kit (Ambion Inc.) was used to remove contaminating 
DNA from extracted RNA. The SuperScript™ III First-Strand Synthesis 
System for RT-PCR kit (Invitrogen, CA) was used to synthesize cDNA 
from extracted RNA. Vector NTI program was used to design relevant 
primers for the PCR amplification. PCR Master Mix kit (Fermentas) was 
used to carry out the PCR and the PCR product was analyzed on a 1.5% 
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Step Conditions cycles 
1 94°C, 3 min 1 
2 94°C, 45 sec 
30 3 55°C, 45 sec 
4 72°C, 30 sec 
5 4°C hold 
Table 2.3 PCR conditions for amplification of cDNA extract from NSC or 
U87 cells 
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2.5 Cell Transduction 
2.5.1 U87 Cells 
3 X 106 U87 cells per well were seed in a 6-well plate and allowed to 
attach for overnight at 37°C, 5% CO2. The medium was replaced with 
fresh DMEM. Baculovirus supernatant was then added at multiplicity of 
infection (MOI) of 20, 50 and 100. After 1-2 hours incubation at 37°C, 5% 
CO2, DMEM containing virus was removed and replaced with fresh U87 
growth medium which is described in section 2.1. Cells were harvested 
and counted 1 day after transduction. 
 
2.5.2 Neural Stem Cells 
When the NSCs were 90% confluent in 6-wells plate, the cells were 
trypsinized and counted. Baculovirus supernatant was added to 
medium at MOI=100 according to the cell number. Medium containing 
virus was replaced with fresh NSC medium after incubation overnight at 
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2.6 Transduction Efficiency Assay by FACS Analysis 
NSC or U87 cells were transduced with baculovirus containing EGFP 
gene 1 day before the fluorescence-activated cell sorting (FACS) 
analysis. Cells were trypsinized and resuspended in PBS before 
analysis with the FACS Calibur flow cytometer (BD Biosciences, San 
Diego, CA, USA). Nontransduced cells were set as control. 
 
2.7 Cell Viability Assays 
2.7.1 MTS Assay 
Cell viability was measured by MTS assay. 20 μl CellTiter 96 AQueous 
One Solution Reagent (Promega) was added into each well of the 
96-well plate containing the samples in 100μl of culture medium. After 
1-4 hours incubation at 37°C, 5% CO2, the absorbance was recorded at 
490nm using a 96-well plate reader. 
 
2.7.2 MTS Assay for 5-FU Sensitivity of Glioma Cells 
U87 cells were seeded in 96-well plate at density of 1000 cells per well 
and allowed to attach overnight. Fresh U87 culture medium containing 
5-FU was used to replace the old medium every other day. MTS assay 
was performed to evaluate cytotoxicity after 5 days 5-FU treatment.  
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2.7.3 MTS Assay for Prodrug Cytotoxicity without Suicide Gene 
U87 cells were seeded in 96-well plate at density of 1000 cells per well 
and allowed to attach overnight. Fresh U87 culture medium containing 
5-FC or GCV was used to replace the old medium every other day. MTS 
assay was performed to evaluate cytotoxicity after 5 days prodrug 
treatment.  
 
2.7.4 MTS Assay for Prodrug Cytotoxicity with Suicide Gene 
U87 cells were transduced by recombinant baculovirus at MOI of 20, 50 
and 100. After one day, the transduced cells were trypinized and 
seeded in 96-well plate at density of 1000 cells per well. Cells were 
allowed to grow overnight to attach. Fresh U87 cell culture medium 
containing 5FC or GCV was used to replace the old medium. After 5 
days of 5-FC or GCV treatment, MTS assay was performed to evaluate 
cytotoxicity.  
 
2.7.5 MTS Assay for Examining Bystander Effects 
2.7.5.1 Tranduced U87/NSC and nontransduced U87 Direct 
Coculture. 
U87 cells or NSCs were transduced by recombinant baculovirus at MOI 
of 100. After one day, the transduced cells were trypinized and mixed 
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with nontransduced U87 cells at ratio of 1:0, 1:1, 1:3 and 
1:9(transduced U87: nontransduced U87) or 50:50, 20:80, 10:90, 5:95 
and 2:98 (transduced NSCs:nontransduced U87). NSCs and U87 cell 
mixture were seeded in 96-well plate at density of 1000 or 2000 cells 
per well, respectively, and allowed to attach overnight. Fresh U87 or 
NSC cell culture medium containing 5FC or GCV was used to replace 
the old medium. After 5 days of 5-FC or GCV treatment, MTS assay 
was performed to evaluate cytotoxicity 
 
2.7.5.2 Transduced NSC and nontransduced U87 Indirect 
Coculture 
NSCs were transduced by recombinant baculovirus at MOI of 100 one 
day before cell seeding. Transduced NSCs were trypsinized and 
seeded in upper chamber of transwell 96-well plate at density of 1000 
cells per well. U87 cells were seeded in bottom well at density of 1000 
cells per well. Fresh NSC cell culture medium containing 5FC or GCV 
was used to replace the old medium. After 5 days of 5-FC or GCV 
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2.8 Animal studies 
Each adult Balb/c nude mouse received subcutaneously injection of 1.5 
X 106 U87-luc cells to establish glioma xenograft model. Eight days after 
tumor inoculation, mice were divided into 4 groups for intratumoral 
injection of PBS or 1 X 105 NSCs expressing HSVtk, CodA or Fcy gene. 
Daily Intraperitoneally injection of 500 mg/ml/kg 5-FC or 50 mg/ml/kg of 
GCV as treatment or PBS as control were given 10 days after tumor 
inoculation. Duration of drug administration was 14 days. Tumor size 
was measured and analyzed by detection of bioluminescent singles of 
U87-luc cells using IVIS imaging system (Xenogen, Alameda, CA, USA) 
and Xenogen living imaging software v2.5. Each mouse received 
intraperitoneally injection of 200 μl of D-luciferin (5mg/ml, Promega) 
dissolved in PBS 20 minutes before luminescent images taking to 
generate bioluminescent signals. All the experiments were performed 
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3.1 Construction of Baculoviral Vectors 
The CodA and Fcy genes were successfully cloned in the pFastBac1 
vector, as shown in Figure 3.3. EcoRI and XhoI enzymes were used for 
c l o n i n g  t h e  C D  g e n e s  i n t o  t h e  p F a s t B a c 1  v e c t o r . 
  
Figure 3.1 Agarose gel photographs of PCR products of CodA(1.3kb) 
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3.2 In Vitro Sensitivity of Glioma Cells to Activated Prodrug 
The cytotoxic effect of 5-FU was assessed by measuring the viability of 
the U87, T98G and SW1783 glioma cell lines. In the T98G cell line, 
inhibition of cell growth was observed 5 days after 5-FU treatment, and 
as the concentration of 5-FU increased, the cytotoxic killing effect was 
enhanced. As shown in figure 3.2, a toxicity of 77.9 ± 2.2% killing effect 
was observed at 30 μg/ml 5-FU. Approximately 60% inhibition was 
observed at 10 μg/ml 5-FU in SW1783, but the cytotoxic killing effect 
remained at 60% as the 5-FU concentration increased. Thus, it is 
possible that a significant proportion of our SW1783 cells have 5-FU 
resistance. The highest cytotoxic effect of 5-FU was observed in the 
U87 cell line. The LD50 was approximately 0.75 μg/ml, which is much 
lower than that in T98G and SW1783 cell lines (LD50s > 2.5 μg/ml). 
Only 13.7 ± 2.2%  U87 cells survived with 10 μg/ml of 5-FU, and the 
viability further decreased to 8.3 ± 1.3% when the concentration of 5-FU 
was increased to 30 μg/ml. These results suggested that U87 had the 
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3.3 Cytotoxic Effects of Prodrugs without the Suicide Gene 
To determine the concentration of prodrug to be used in subsequent 
experiments, we first tested the cytotoxic effect of 5-FC and GCV on 
non-transduced U87 cells in vitro. Concentrations of up to 200 μg/ml 
5-FC itself did not inhibit cell growth, whereas 7.6 ± 6.0% and 26.8 ± 5.2% 
inhibition were observed at higher concentrations of 5-FC (Figure 3.3). 
No significant cytotoxic effect was observed until the concentration of 
GCV reached 20 μM; inhibition of 10.0 ± 9.2 % and 26.3 ± 10.0% was 


























 (a)                            (b) 
 
Figure 3.3. Cytotoxic effects of prodrugs on non-transduced U87 cells. 
The graphs show the cell viability of non-transduced U87 cells after 5 
days of treatment with 5-FC (a) or GCV (b). Each bar represents the 
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3.4 In Vitro Comparisons of Three Suicide Gene/Prodrug Systems 
3.4.1 The Transduction Efficiency of Baculoviruses 
Baculoviruses can transduce U87 cells, and the expression of the 
transgene can be maintained for at least 2 weeks. The 
CMV-eGFP-WPRE baculoviral vector, which expresses fluorescent 
eGFP, was used to measure baculovirus transduction efficiency in U87 
cells. As shown in Figure 3.4 and Table 3.1, the transduction efficiency 
increased with an increase in MOI. The percentages of eGFP-positive 
U87 cells were nearly 100% at all MOI tested and the mean 




















(a)               (b)               (c)
 
Figure 3.4. U87 cells transduced with baculovirus expressing the eGFP 
gene at MOI of 20 (a), 50 (b) and 100 (c). Pictures were taken with a 
digital camera attached to an Olympus IX71 inverted fluorescence 
microscope 1 day after transduction. 
 
MOI 20 50 100 
Transduction efficiency (%) 98.10 99.29 99.81 
Mean fluorescence intensity 5060.63 7294.11 8540 
Table 3.1 Transduction efficiency and mean fluorescence intensity of 






MOI=20 MOI=50 MOI=100 
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3.4.2 In Vitro Sensitivity of Transduced Glioma Cells to Prodrug 
The HSVtk/GCV and CD/5-FC systems are commonly used in cancer 
gene therapy, and both exhibit strong anti-tumor effects. To compare 
the killing effect of these suicide gene/prodrug systems, we constructed 
baculoviral vectors expressing the suicide genes HSVtk, E. coli CD 
CodA and yeast CD Fcy with the CMV promoter and WPRE. 
Expression of HSVtk and CD followed by the administration of the 
prodrugs GCV and 5-FC, respectively, kills the transduced cells, as well 
as neighboring cells, through a bystander killing effect.  
 
To test the in vitro sensitivity of transduced U87 cells to the prodrugs, 
U87 cells that were transduced at different MOI (from 20 to 100) were 
seeded in 96-well plates 1 day after transduction and cultured in 
medium containing 10 μM GCV or 200 μg/ml 5-FC, which represent the 
maximum prodrug dosage that does not cause cytotoxic effects (Figure 
3.3), for 5 days (Figure 3.5a). At MOI of 20, > 80% of HSVtk-expressing 
U87 cells were killed after 5 days of GCV treatment. However, only 
approximately 55% of CodA- or Fcy-expressing U87 cells were killed 
after 5-FC treatment. With an increase in MOI, HSVtk-expressing U87 
cells maintained an ~80% killing effect; 23.1 ± 4.9% and 16.0 ± 7.9% 
cell viability was observed at MOI of 50 and 100, respectively. When 
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MOI increased, the viability of CD-expressing cells decreased 
significantly. The viability of CodA-expressing U87 cells decreased from 
54.4 ± 6.7% at MOI of 20 to 37.4 ± 4.4% at MOI of 50 and 33.0 ± 5.3% 
at MOI of 100. A significant cell viability decrease was similarly 
observed in Fcy-expressing cells with cell viability decreased, from 56.4 
± 4.0% at MOI of 20 to 33.6 ± 2.8% at MOI of 50 and 31.0 ± 4.0% at 
MOI of 100. Although the CD-expressing U87 cells produced a stronger 
killing effect at higher MOI, the cell viability of HSVtk-expressing U87 
cells was significantly lower than CodA- and Fcy-expressing cells at all 
MOI, indicating that U87 cells expressing HSVtk are more sensitive to 
GCV than CD-expressing U87 cells. Suicide gene expression followed 
by prodrug treatment achieved the highest killing effect at MOI of 100 in 
all groups. Therefore, MOI was fixed at 100 in subsequent experiments.  
 
To further test the in vitro sensitivity of transduced U87 cells to the 
prodrugs, cells transduced with BV-HSVtk, BV-CodA or BV-Fcy (at MOI 
of 100) and determined to be expressing the suicide genes were 
subjected to prodrug treatment at various concentrations. Transduced 
U87 cells were cultured and treated with various concentrations of GCV, 
ranging from 1 to 20 μM, or 5-FC, ranging from 50 to 500 μg/ml. After 5 
days of treatment with 50 μg/ml 5-FC, 80.0 ± 12.3% of Fcy– and 58.9 ± 
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12.9% of CodA-expressing U87 cells survived (Figure 3.5b). The cell 
viability decreased to ~33% when the concentration of 5-FC was 
increased to 200 μg/ml. Cell survival continued to decrease when the 
concentration increased from 200 to 500 μg/ml. However, this additional 
~10% killing effect may be due to a nonspecific effect of 5-FC at high 
concentrations (Figure 3.3a). HSVtk-expressing U87 cells treated with 
GCV also displayed dose-dependent cytotoxic killing effects. This cell 
viability decreased from 36.1 ± 10.0% at 1 μM GCV to ~5% at 10 and 20 
μM GCV (Figure 3.5c). Concentrations as low as 1 μM of GCV 
produced cytotoxic effects in HSVtk-expressing U87 cells that were no 
worse than the killing effects of 200 μg/ml 5-FC on CodA- and 
Fcy-expressing U87 cells. Combined with our previous results (Figure 
3.5a), these data indicate that the in vitro sensitivity of 
HSVtk-expressing U87 cells to GCV is superior to that of CodA- and 
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3.4.3 Comparisons of Bystander Effects 
To test the bystander effect, baculovirus-transduced U87 cells and 
non-transduced U87 cells were mixed at different percentages 
(between 10% and 100%) one day after transduction and cultured in 
U87 culture medium containing GCV or 5-FC for 5 days before 
measuring viability. 1 μM GCV and 200 μg/ml 5-FC were used in this 
experiment because Tk- and CD- expressing U87 cells produced similar 
anti-tumor effects under these concentrations. 
 
As shown in Figure 3.6, when all of the U87 cells were transduced, the 
cell survival in HSVtk and CD groups were approximately 35% and the 
difference between them was insignificant. When the percentage of 
transduced U87 decreased to 50%, the killing effect of 
HSVtk-expressing U87 cells decreased to 52.2 ± 3.8%, while the 
anti-tumor effects of CodA- and Fcy-expressing U87 cells increased 
(but not significantly) from 61.7 ± 3.2% to 66.8 ± 3.1% and 67.9 ± 5.9% 
to 73.5 ± 3.6%, respectively. The killing effect of HSVtk-expressing U87 
cells significantly decreased when the percentages of transduced U87 
cells were further decreased to 25 and 10%; these decreases were 
associated with 41.8 and 45.1 decreases in viability, respectively, 
whereas a < 15% decrease of killing effect was observed in CodA- and 
  47 
 
Fcy-expressing cells. The cell viability of HSVtk-expressing U87 cells 
was significantly higher than CodA- and Fcy-expressing cells when the 
percentage of transduced cells was < 50%, indicating that the CD/5-FC 
system produces a stronger bystander effect than the HSVtk/GCV 
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To further test the bystander effect of transduced NSCs, we prepared 
cell mixtures by mixing the baculovirus-transduced NSCs and U87 cells 
at ratios of 50 to 50. These cells were then cultured in NSC culture 
medium containing GCV or 5-FC for 5 days. NSCs could be transduced 
effectively by baculovirus at MOI of 100; up to 99% of NSCs were 
transduced (Figure 3.7a). Coculture of transduced NSCs and U87 
treated with GCV or 5FC displayed dose-dependent cytotoxic killing 
effects. This killing effect of TK/GCV increased from 25.3% ± 4.3% at 
0.1 μM GCV to ~70% at 10 μM GCV while that of Coda/5FC and 
Fcy/5FC increased from almost 0% at 10 μg/ml 5FC to ~75% at 200 
μg/ml 5FC(Figure 3.7 b and c). Only less than 15% of cell death caused 
by prodrug without expression of suicide genes was recorded (Figure 
3.7 b and c) which suggested that the killing effect of transduced NSCs 
is mostly because of the cytotoxic effect coming from the combination of 

















Figure 3.7. Neural stem cells transduced with baculovirus expressing 
the eGFP gene at MOI of 100 (a) and the in vitro cytotoxicity of suicide 
genes expressing NSCs against U87 cells under different concentration 
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To further test the bystander effect of transduced NSCs, we prepared 
cell mixtures by mixing suicide gene expressing NSCs and the wild-type 
U87 at ratios ranging from 2:98 to 50:50(Figure 3.8a). These cells 
mixtures were cultured in NSC culture medium containing 10 μM GCV 
or 200 μg/ml 5-FC for 5 days and then subjected to MTS assay. 
 
As shown in Figure 3.8a, when the ratio of NSCs to U87 was 50:50, the 
cell viability was 25.7 ± 5.5% in the presence of HSVtk-expressing 
NSCs; while the viability of Fcy was significantly higher (CodA was 
higher but not significantly). When the NSCs: U87 cells ratio decreased 
to 20:80 or less, the killing effects of HSVtk-expressing NSCs 
decreased significantly. Only an ~40% killing effect was observed when 
the ratio of NSC:U87 was 20:80, and almost no killing effects were 
observed at ratios of 5:95 and 2:98 in which the inhibition of cell growth 
was approximately 8 and 2%, respectively. The anti-tumor effects of 
Coda and Fcy also decreased with the decrease in the NSCs: U87 cells 
ratio. However, both CodA and Fcy groups maintained ~40-50% killing 
effects, which were significantly higher than the killing effects of HSVtk; 
approximately 40% of the killing effects could still be achieved, even at 
a ratio as low as 2:98. The CD/5-FC system has a stronger bystander 
effect than the HSVtk/GCV system, which enables the CD/5-FC system 
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to produce more powerful anti-tumor effects. Thus, even a small 
amount of cells encoding the suicidal proteins were enough to generate 
a promising killing effect.  
 
Because the close contact of cells plays key role in bystander effect of  
HSVtk/GCV system but the certain proximity is not required in that of  
CD/5-FC system, we designed an indirect co-culture experiment to 
further compare the anti-tumor effects between these two suicide 
gene/prodrug systems(Figure 3.8b). We prepared NSCs expressing 
HSVtk or CD, seeded them in the upper chamber of a transwell, and 
seeded the U87 cells in the bottom well to completely avoid cell-to-cell 
contact. The number of NSCs of upper chamber and U87 cells of 
bottom well is equal. Compared to direct culture, the killing effect of 
HSVtk-expressing NSCs decreased the most, by 48.1%, while the 
effects of CodA- and Fcy-expressing cells decreased by only 20.5 and 
13.6%, respectively (Figure 3.8b). Only ~30% of U87 cells were killed in 
the indirect co-culture with HSVtk-expressing NSCs, whereas over half 
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3.5 In vivo Comparisons of Three Suicide Gene/Prodrug Systems 
Having tested and compared the in vitro efficiency of the HSVtk/GCV 
and CD/5-FC systems in killing U87 cells, we next examined and 
compared the anti-tumor efficiency of both systems in vivo. The fold 
change in tumor volume is shown in Figure 3.7a, and the tumor volume 
detected by the IVIS imaging system at day 14 is shown in Figure 3.7b.  
 
Our previous study revealed that mesenchymal stem cells expressing 
HSVtk are able to slow down tumor growth (Bak et al., 2010). CD 
expressing-Neural stem cells also produced strong inhibitory effects on 
various tumors (Aboody et al., 2006; Joo et al., 2009; Kim et al., 2006; 
Shimato et al., 2007). Two mice subcutaneously injected with 
U87-luciferase cells into the root of the right and left thigh were 
sacrificed at 10 days after tumor inoculation-the exact day we start 
prodrug treatment. The tumors were removed and trypsinized in order 
to count the number of U87-luc cells. The number of inoculated U87-luc 
cells was approximately 1-2 x 107 (data not shown) at day 1. The ratio of 
transduced NSCs to U87-luc cells in vivo was approximately 0.5-1 to 
100.  
 
After 1 week of 5-FC administration, tumor volumes decreased to 
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approximately 20% in both CD groups, whereas the tumor volume 
increased 18% (which is significantly higher than that in the NSC-CD 
group) in the NSCtk group after GCV treatment. Tumor recurrence 
observed at day 14 is likely resulted from the transient expression of the 
transgene mediated by the baculovirus, which may limit the application 
of baculoviruses in cancer gene therapy. At 14 days of treatment, up to 
6.3-fold increases were observed in the HSVtk group, whereas the 
tumor volume in the groups of Fcy and Coda genes increased 3.6 and 
5.3-fold, respectively. The in vivo inhibitory effect of the CD/5-FC 
system on tumor growth was more pronounced than the HSVtk/GCV 
system (though the differences were not significant at days 14 between 
Coda/5FC and HSVtk/GCV), indicating that the CD/5-FC system is able 
to induce a stronger bystander effect, even when the number of 
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injection of different numbers of transduced NSCs and i.p injection of 
the prodrugs GCV or 5-FC. (a) Fold change of the tumor volume 
compared to the tumor volume at day 1. The duration of treatment was 
14 days. ** p<0.001 vs the fold change of tumor volume of PBS control; 
* p<0.05 (b) Tumor volume detected by the IVIS imaging system at day 
14. Each spot represents the average fold change of tumor volume 
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In this study, baculoviral vectors expressing HSVtk, yCD (Fcy) or bCD 
(CodA) were constructed and used to produce bacolovirus to transduce 
U87 cells and NSCs and examine their anti-tumor effects in vitro and in 
vivo. The in vitro data suggested that when U87 cells were transduced 
with the three different baculoviruses at MOI of 100, the HSVtk/GCV 
system caused more profound inhibitory effects on tumor development 
than the CD/5-FC system (Figure 3.5b and c). A reduction in MOI for 
transduction significantly reduced the anti-tumor effect of CD/5-FC from 
~70 to ~40-50%. However, survival of HSVtk-transduced U87 cells 
remained at ~15-20% (Figure 3.5a). A significant anti-tumor effect 
reduction was observed in CD-transduced cells when more U87 cells 
were initially seeded in a 96-well plate, whereas no significant reduction 
was observed in HSVtk-transduced U87 cells (data not shown). When 
U87 cells were seeded at 2,000 cells per well, a killing effect of only 
~20-30% was observed in CD-transduced cells. When the seeding 
density was increased to 5,000 cells per well, the antitumor effect was 
minimally observed in CD-transduced U87 cells, which was similar to 
non-transduced U87 cells with 5-FC treatment. In contrast, cells were 
seeded at 1,000 cells/well in a 96-well plate, CD-transduced U87 cells 
exhibited a > 50% reduction in the tumor cell viability compared to the 
condition in which CD-transduced U87 cells were seeded at a higher 
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density. A > 70% killing effect was achieved in HSVtk-transduced cells, 
even if 5,000 cells/well were seeded at the beginning of the experiment. 
These results suggest that glioma cells exhibit a higher sensitivity to the 
prodrugs in the HSVtk/GCV system than in the CD/5-FC system. The 
half-life of GCV is estimated to be approximately 100 min, whereas that 
of 5-FC is only 40 min (Quynh et al., 1995). The longer half-life of GCV 
suggests the possibility that more GCV is able to be enzymatically 
converted to the cytotoxic chemotherapy agent GCV triphosphate, 
which may be the possible explanation for the difference in the 
antitumor effect between HSVtk- and CD-transduced U87 cells. 
Furthermore, 5-FU resistance is possible. Approximately 8% of 
CD-transduced U87 cells remained alive 5 days after 5-FU treatment, 
even at the high 5-FU dosage of 30 μg/ml. 5-FU has been used as an 
anti-tumor chemotherapy agent for over 50 years (Curreri et al., 1958), 
and resistance to 5-FU results from excessive expression of thymidylate 
synthase (TS), which is the target of 5-FU. TS gene overexpression is a 
signature feature of 5-FU resistance (Longley et al., 2003). Deregulated 
expression of TS in tumor cells increases the expression of the free 
enzyme, which allows it to escape from irreversibly binding 5-FU, 
resulting in 5-FU resistance. The direct use of 5-FU does not have 
much effect against brain tumors. Enhanced TS activity has been found 
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in high-grade gliomas compared to TS activity in a normal brain (Bardot 
et al., 1994), suggesting that glioma cells may be resistant to 5-FU 
treatment. In addition to the overexpression of TS, Qian et al. (2007) 
have reported that Smug1 DNA glycosylase can excise the DNA which 
was incorporated with 5-FU and therefore may reduce the drug’s 
cytotoxicity which is considered another mechanism of 5-FU resistance. 
The concentration of prodrug needed to exhibit cytotoxicity is much 
higher in the CD/5-FC system than in the HSVtk/GCV system, which 
may explain the lower antitumor effect in CD-transduced cells. As 
shown in Figure 3.5b and c, a satisfactory inhibitory effect in 
HSVtk-transduced U87 cells was achieved at concentrations as low as 
1 μM GCV. A similar antitumor effect in CD-transduced U87 cells could 
be achieved only when the concentration of 5-FC was increased to 150 
μg/ml. Under conditions in which transduced U87 cells were seeded in 
96-well plates at a higher concentration, 10 μM GCV may still have 
been enough to produce the antitumor effect, whereas 200 μg/ml 5-FC 
may not have been sufficient to generate enough 5-FU above the 
threshold required to kill glioma cells. 
 
Following prodrug treatment, cells expressing suicide genes die 
themselves and more importantly are able to kill neighboring cells by 
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inducing cell death. This property is known as the bystander effect. 
Because current technology does not allow the delivery of the suicide 
gene to all tumor cells, the bystander effect is crucial in cancer suicide 
gene therapy and plays an important role in determining the efficiency 
of suicide gene/prodrug systems. Only 10% of HSVtk-expressing cells 
are able to produce a strong antitumor bystander effect and result in 
complete in vivo tumor regression (Caruso et al., 1993; Culver et al., 
1992; Ram et al., 1993). Furthermore, the bystander effect of the 
HSVtk/GCV system relies on close cell-to-cell contact through gap 
junctions (Fick et al., 1995; Pitts 1998). In contrast, because 5-FU is 
able to diffuse through the cell membrane by non-facilitated diffusion 
into neighboring cells (Huber et al., 1994; Miller et al., 2002), it is able to 
diffuse to more distant cells, and close range cell contact is 
unnecessary. 
 
The bystander effect of CD/5-FC is independent of gap junctions, 
suggesting that CD/5-FC is stronger than the HSVtk/GCV system for 
tumor therapy, especially because gap junctions are downregulated in 
most cancer cell lines (Holder et al., 1993). As a matter of fact, CD/5-FC 
system is reported to have more powerful activity in the in vitro 
eradication of several cancer cell lines (Kuriyama et al., 1999; Rogers et 
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al., 1996; Trinh et al., 1995). Consistent with previous studies, we 
confirmed that the CD/5-FC system exhibited a stronger bystander 
effect than the HSVtk/GCV system (Figure 3.6 and Figure 3.7a). A 10% 
transduction of U87 cells with CD was able to elicit a > 50% antitumor 
effect, whereas a 10% transduction with HSVtk resulted in only 10% cell 
death (Figure 3.6). An inhibitory effect towards cell growth was 
minimally recorded when HSVtk-transduced NSCs were mixed with 
U87 cells at a low ratio of 2:98. However, CD-transduced NSCs mix 
with U87 at the same ratio exhibited an ~40% antitumor effect (Figure 
3.8a). A transwell system was employed to test whether close range cell 
contact is necessary for the bystander effect of both systems. Not 
surprisingly, physical contact was not essential in the bystander effect 
induced by CD/5-FC. However, a significant reduction in the bystander 
effect caused by HSVtk/GCV was observed in the absence of close 
cellular proximity (Figure 3.8b). 
 
Although the major protein comprising the gap junction, connexin-43, is 
down-regulated or even completely lost in different tumors (Laird et al., 
1999; Mehta et al., 1999; Mesnil et al., 2005; Tsai et al., 1996), 
gap-junctional intercellular communication (GJIC) is preserved in 
human glioblastoma cells. Cottin et al. (2008) reported that glioblastoma 
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cell surface expresses only few gap junctions, whereas most of the 
connexin-43 is presented in lysosomes and late endosomes. Their 
results suggested that gap junctions are highly functional in 
glioblastoma cells, demonstrating the value of HSVtk/GCV therapy. 
Although gap junctions are highly functional in U87 compared to other 
tumor types, the bystander effect caused by HSVtk/GCV is inferior to 
that caused by CD/5-FC, clearly suggesting the superiority of the 
CD/5-FC system.  
 
We used the transwell system to fully avoid physical contact between 
HSVtk-transduced NSCs (that were seeded in the upper chamber) and 
U87 cells (that were seeded in the bottom chamber). An ~30% 
antitumor effect remained in the absence of close range of cell contact, 
indicating that the gap junction may not be the sole means for 
HSVtk/GCV to exhibit its bystander effect. Transfer of apoptotic vesicles 
and exocytosis of cytotoxic factors (Barba et al., 1994; Freeman et al., 
1993) may be another mechanism underlying the transmission of 
cytotoxic chemotherapeutic agents from HSVtk-expressing cells to 
other cells after GCV treatment. 
 
Several approaches have been used to enhance the antitumor effect of 
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suicide gene/prodrug systems. Because gap junctions play key role in 
bystander effect of HSVtk/GCV, restoring these junctions may upgrade 
this system and enhance its ability to eradicate tumor cells. Huang et al. 
(2010) demonstrated that the HSVtk/GCV bystander effect is amplified 
in bone marrow-derived stem cells expressing HSVtk associated with 
the over-expression of connexin-43 when connexin-43 is introduced 
into glioma cells.  
Yeast-derived CD (yCD or Fcy in this study) and bacterial CD (bCD or 
CodA in this study) are two distinct forms of CD. yCD is less 
thermostable than bCD, and the product released from CD is rate 
limiting (Katsuragi et al., 1987; Yao et al., 2005). However, yCD displays 
superior kinetic properties toward 5-FC and a slightly improved 
antitumor effect than bCD in vivo (Kievit et al., 1999). In our study, no 
significant difference between the anti-glioma effect of yCD and bCD 
was observed either in vitro or in vivo, indicating that the application of 
both CD genes is feasible in glioma gene therapy. 
 
Increasing the intracellular concentration of the prodrug is one strategy 
for increasing the efficacy of CD/5-FC. The combination of E. coli CD 
and uracil phosphoribosyl transferase (UPRT) significantly improves the 
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therapeutic effect of CD/5-FC by direct conversion of 5-FU into 
5-fluorouridine monophosphate (5-FUMP) (Koyama et al., 2000). 
Extracellular expression of CD is another approach to increase the 
antitumor effect of CD/5-FC. A high intracellular concentration of 5-FU 
may result in the premature killing of CD-expressing cells and a shut 
down of the ‘5-FU factory’, even before the cytotoxic extracellular 
concentration of 5-FU is achieved (Lawrence et al., 1998). Rehemtulla 
et al. (2004) constructed a soluble, secreted form of CD and achieved 
gradual inhibition of TS, which prolongs the survival time of 
CD-expressing cells and improves the bystander effect. Genetic 
modification of the CD gene also improves the therapeutic effect of 
CD/5-FC. A mutated E. coli CD has a higher affinity for cytosine, which 
results in a superior in vitro antitumor effect towards glioma cells than 
wild type CD. In vivo analysis has also revealed a large inhibition of 
tumor growth by the combination of mutated CD/5-FC plus ionizing 
radiation compared to wild type CD/5-FC with radiation (Kaliberov et al., 
2007).  
 
Both in vitro and in vivo results demonstrate that the CD/5-FC system 
induces stronger bystander effect compared with HSVtk/GCV system. 
Quynh et al. (1995) reported that as little as 4% expression of CD in the 
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WiDr human colorectal carcinoma cell line can produce a remarkable 
bystander effect, with 60% of the mice remaining tumor-free up to day 
70, whereas 50% expression of HSVtk in WiDr cells is needed to 
achieve the same effect (Quynh et al., 1995). In our experiments, during 
the first week of treatment when baculoviral-mediated transgene 
expression was significantly strong, the tumor volume decreased after 
NSC-CD intratumoral injection and 5-FC administration (Figure 3.9a). In 
contrast, in another group of mice injected with NSC-tk, the tumor 
volume increased. Compared to the number of tumor cells injected at 
day 1, the injected NSCs were very limited. However, the strong 
bystander effect induced by NSCs expressing CD was still able to exert 
a promising inhibitory effect on tumor development when the ratio of 
injected NSCs to tumor cells was < 1:100. Because only a limited 
percentage of injected NSCs can migrate from a distant injection site to 
the tumor mass or satellite sites, a strong bystander effect elicited by 
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In summary, we demonstrated that the CD/5-FC system is superior to 
the HSVtk/GCV system both in vitro and in vivo. Our in vitro data 
reveals that although the sensitivity of CD to 5-FC is inferior to that of 
HSVtk to GCV; the CD/5-FC system displays stronger inhibitory effects 
on tumor growth than the HSVtk/GCV system by inducing a stronger 
bystander effect. We also prove that the bystander effect caused by 
CD/5-FC does not require close proximity cell contact, which is the key 
factor in the bystander effect induced by HSVtk/GCV. The in vivo results 
also support the superiority of the CD/5-FC system over the 
HSVtk/GCV system. Our data suggests that the strong bystander effect 
induced by the CD/5-FC system enables limited CD-expressing NSCs 
to inhibit tumor growth in vivo. In addition, no difference was observed 
between the yCD/5-FC system and the bCD/5-FC system, indicating 
the feasibility of using both CD/5-FC systems in glioma gene therapy. In 
conclusion, our findings demonstrate the superiority of the CD/5-FC 
system over the HSVtk/GCV system and provide a more effective 
suicide gene/prodrug system for future glioma gene therapy using 
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